FREE FORM DOCUMENT: CAN INCLUDE TEXT, HYPERLINKS, IMAGES AND EMBEDDED VIDEOS

The Information Source for the Pharmaceutical Manufacturing Industry

Welcome to Pharmaceutical Online, the premier sourcing site for the pharmaceutical manufacturing industry, find industry information on critical environment, particle sizing, pharma process control, pharma material handling, tablet production, pharma sterilizing, pharma cleaning, pharma filtration, pharma packaging, pharma inspection, & much more. Use our product showcase, and offline search service to expedite your discovery of new products and services. Our goal is to help buyers, like you, identify and select suppliers.

Pharmaceutical Online is part of the Life Science Connect media group. The vision of Life Science Leader and Life Science Connect is to help facilitate connections and foster collaborations in pharmaceutical and medical device development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute. Please take a moment to join our community and discover the benefits of your free membership.

IMAGE TITLE SUMMARY DISPLAY

TITLE SUMMARY DISPLAY

  • Versatile Pharmaceutical Weighing Platform That Provides High Accuracy And Throughput

    This video demonstrates the C3570 checkweigher system's extremely high weighing accuracy (from +/- 10 mg) on packages from 3g to 10kg. It is capable of running up to 600 packs per minute with product handling variants including side-grip conveyors, top and bottom conveyors, infeed timing screws and star-wheels which ensure smooth product flow.

  • Vision Inspection For Un-oriented Round Packages

    See the V15 vision system perform product data checks to catch labeling errors including 1D and 2D barcodes and alpha-numeric text. We will demonstrate how quickly product changeovers can be handled and the system's user-intuitive HMI.

  • Intelligent Optimum X-ray Inspection

    Learn how the revolutionary X34 x-ray inspection system reliably detects and rejects a variety physical contaminants for ultimate brand protection. Its proprietary class-leading software enables minimal false rejects, significantly reducing product waste. We will walk you through its user-intuitive interface and the automatic product set up feature which delivers increased uptime.

GRID WITH IMAGE DISPLAY

Our industry has, with not insignificant regulatory assistance, obstructed the implementation of a technology that has proven safe and effective and was an enormous improvement over the conventional cleanrooms universally in place in the mid-1980s.

NASH has remained a relative graveyard of drug development over the past 40 years: no disease-specific approved therapies have made it to market. This article analyzes the first wave of drugs (at Phase 3) poised to change the NASH management paradigm and shape the ambiguous pricing and reimbursement landscape.

When it comes to current good manufacturing practice (cGMP) compliance, many sponsors lose sight of their responsibility to ensure that each gram or dose of externally derived output fully meets its registered parameters and has been demonstrated by the contract manufacturing organization as manufactured in full compliance with the requirements of cGMP.

It seems pitiful that, for whatever reason, industry has failed to universally adopt more effective technologies to control contamination resulting in safer sterile drugs. On the other hand, the regulators must share substantial blame because of their historically lukewarm acceptance of emerging and even established advanced technologies.

SLIDESHOW DISPLAY - IMAGE REQUIREMENT = 745X400 PIXELS

CONTACT INFORMATION

Pharmaceutical Online

5340 Fryling Road

Erie, PA 16510

UNITED STATES

Phone: 814-897-7700

TITLE SUMMARY DISPLAY

GRID WITH IMAGE DISPLAY

Our industry has, with not insignificant regulatory assistance, obstructed the implementation of a technology that has proven safe and effective and was an enormous improvement over the conventional cleanrooms universally in place in the mid-1980s.

NASH has remained a relative graveyard of drug development over the past 40 years: no disease-specific approved therapies have made it to market. This article analyzes the first wave of drugs (at Phase 3) poised to change the NASH management paradigm and shape the ambiguous pricing and reimbursement landscape.

When it comes to current good manufacturing practice (cGMP) compliance, many sponsors lose sight of their responsibility to ensure that each gram or dose of externally derived output fully meets its registered parameters and has been demonstrated by the contract manufacturing organization as manufactured in full compliance with the requirements of cGMP.